Auditory MMN EEG in TRD in Response to Ketamine

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions
Treatment-resistant Depression (TRD)
Interventions
DRUG

Ketamine

Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.

Trial Locations (1)

M5B1M8

RECRUITING

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

Centre for Addiction and Mental Health

OTHER

collaborator

Toronto Metropolitan University

OTHER

lead

Unity Health Toronto

OTHER